Abbisko Cayman's (HKG:2256) unit, Abbisko Therapeutics, reported "positive top-line results" for its Phase 3 MANEUVER study of pimicotinib after the study met primary endpoint with a response rate of 54% at week 25 compared with 3.2% for placebo, according to a Tuesday filing with the Hong Kong bourse.
Pimicotinib, a small molecule inhibitor of CSF-1R, has shown positive results in patients with tenosynovial giant cell tumor, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.